VC  Vida Ventures

https://vidaventures.com/





     Office Locations:

40 Broad Street, Suite 201
Boston, MA 02109
Phone: 857-254-9500

Get all office locations for this firm with a National Database subscription or Southern California Database subscription.
 

Stages:

  • Early
  • Seed


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    Vida Ventures is a next-generation life sciences investment firm founded in 2017 by a group of scientists, physicians, entrepreneurs and investors passionate about building and funding breakthroughs in biomedicine. Its mission is to bring science to life and advance transformative biomedical innovations that have the potential to make a meaningful difference for patients. Vida has a bicoastal presence and currently manages approximately $1 billion. Vida Ventures can build and back companies regardless of stage and across therapeutic areas.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or Southern California Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Southern California Database subscription.
    Arie Belldegrun M.D. Co-Founder, Sr. Managing Director
    Arjun Goyal M.D., M.Phil, M.B.A. Co-Founder, Managing Director
    David Chang M.D., Ph.D. Scientific Advisor
    Fred Cohen M.D., D.Phil Co-founder & Senior Advisor
    Helen Kim M.B.A. Senior Managing Director

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      08/18/2021


      Vigil Neuroscience


      MA


      $90,000,000


      Series B


      04/06/2021


      Volastra Therapeutics


      NY


      $12,000,000


      Seed


      03/19/2021


      Aktis Oncology


      MA


      $72,000,000


      Series A


      02/16/2021


      Centessa Pharmaceuticals


      MA


      $250,000,000


      Series A


      12/14/2020


      Locana


      CA


      $100,000,000


      Series B


     

    Portfolio companies include:


      A2 Biotherapeutics
        web link


      Aktis Oncology
        web link


      Allogene Therapeutics
        web link


      Askbio


      Centessa Pharmaceuticals
        web link


      Dyne Therapeutics
        web link


      Homology Medicines
        web link


      Iconovir Bio


      Kadiant


      Kinnate Biopharma
        web link


      Kronos
        web link


      Kronos Bio
        web link


      Kyverna Therapeutics
        web link


      Locana
        web link


      Neo Gene Therapeutics


      Oyster Point Pharmaceuticals
        web link


      Pact Pharma


      Pionyr Immunotherapeutics
        web link


      Praxis Precision Medicines
        web link


      ReCode Therapeutics
        web link


      Scorpion Therapeutics
        web link


      Vigil Neuroscience
        web link


      Volastra Therapeutics
        web link


     

    Recent News: